Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer Biology and Prevention in Diabetes
Swayam Prakash Srivastava, Julie E. Goodwin
Cells (2020) Vol. 9, Iss. 6, pp. 1380-1380
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway
Jun Zhou, Jin Zhu, Sheng-Jian Yu, et al.
Biomedicine & Pharmacotherapy (2020) Vol. 132, pp. 110821-110821
Open Access | Times Cited: 119
Cancer and diabetes: the interlinking metabolic pathways and repurposing actions of antidiabetic drugs
Ahmed Olatunde, Manisha Nigam, Rahul Singh, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 59
Endothelial SIRT3 regulates myofibroblast metabolic shifts in diabetic kidneys
Swayam Prakash Srivastava, Jinpeng Li, Yuta Takagaki, et al.
iScience (2021) Vol. 24, Iss. 5, pp. 102390-102390
Open Access | Times Cited: 57
Ferroptosis as a Novel Determinant of β-Cell Death in Diabetic Conditions
Ana Stančić, Tamara Saksida, Milica Markelić, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-19
Open Access | Times Cited: 39
The state of the art in secondary pharmacology and its impact on the safety of new medicines
Richard Brennan, Stephen Jenkinson, Andrew J. Brown, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 7, pp. 525-545
Closed Access | Times Cited: 10
Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials
Rosaria Benedetti, Giuditta Benincasa, Kimberly Glass, et al.
Pharmacological Research (2021) Vol. 175, pp. 106039-106039
Closed Access | Times Cited: 48
Comparison between sodium‐glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real‐world evidence study
Hui‐Lin Sung, Chuan‐Yu Hung, Yu‐Chun Tung, et al.
Diabetes/Metabolism Research and Reviews (2024) Vol. 40, Iss. 3
Closed Access | Times Cited: 6
The impacts of dipeptidyl- peptidase 4 (DPP-4) inhibitors on common female malignancies: A systematic review
Anoosha Niazmand, Reza Nedaeinia, Nasimeh Vatandoost, et al.
Gene (2024) Vol. 927, pp. 148659-148659
Open Access | Times Cited: 4
Lifestyle Factors and Family History of Diabetes as Significant Risks for Breast Cancer: A Hospital-Based Cohort Study in Tamil Nadu, India
Kanagaraj Suganya, Sundaravadivelu Sumathi, Balraj Sudha, et al.
Indian Journal of Surgical Oncology (2025)
Closed Access
Nutrition for Cancer Prevention and Therapy
Visar Vela, Besmira Sabani, Günther Spahn
(2025), pp. 209-240
Closed Access
Loss of Mitochondrial Control Impacts Renal Health
Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 31
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Mariusz Dąbrowski
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1680-1680
Open Access | Times Cited: 26
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer
Zhao Liu, Hiromitsu Hayashi, Kazuki Matsumura, et al.
British Journal of Cancer (2022) Vol. 128, Iss. 5, pp. 844-856
Closed Access | Times Cited: 17
Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes
Christian Sümeghy Søndergaard, Paulina Nuñez Esquivel, Μaria Dalamaga, et al.
Current Oncology Reports (2022) Vol. 25, Iss. 1, pp. 29-40
Closed Access | Times Cited: 16
Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk
Wei‐Syun Hu, Cheng‐Li Lin
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 5, pp. 108468-108468
Closed Access | Times Cited: 9
The complex landscape of intracellular signalling in protein modification under hyperglycaemic stress leading to metabolic disorders
Hamda Khan, Afreen Khanam, Adnan Ahmad Khan, et al.
The Protein Journal (2024) Vol. 43, Iss. 3, pp. 425-436
Closed Access | Times Cited: 3
Exploring the anti-cancer potential of SGLT2 inhibitors in breast cancer treatment in pre-clinical and clinical studies
Yasaman Naeimzadeh, Amir Tajbakhsh, Mahnaz Nemati, et al.
European Journal of Pharmacology (2024) Vol. 978, pp. 176803-176803
Closed Access | Times Cited: 3
Diabetes and Cancer: Metabolic Association, Therapeutic Challenges, and the Role of Natural Products
Wamidh H. Talib, Asma Ismail Mahmod, Sara Feras Abuarab, et al.
Molecules (2021) Vol. 26, Iss. 8, pp. 2179-2179
Open Access | Times Cited: 23
Global, regional, and national time trends in cancer mortality attributable to high fasting plasma glucose: an age-period cohort analysis
Jing Xie, Zeye Liu, Liqun Ren, et al.
BMC Public Health (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 8
Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Chin‐Hsiao Tseng
International Journal of COPD (2022) Vol. Volume 17, pp. 285-295
Open Access | Times Cited: 13
The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells
Maria Francesca Santolla, Marianna Talia, Francesca Cirillo, et al.
Cells (2022) Vol. 11, Iss. 15, pp. 2402-2402
Open Access | Times Cited: 13
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Swayam Prakash Srivastava, Arvind K. Srivastava, Subhash Chand, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 8, pp. 751-751
Open Access | Times Cited: 16
Metformin and Malignant Tumors: Not Over the Hill
Weiling Leng, Juan Jiang, Bing Chen, et al.
Diabetes Metabolic Syndrome and Obesity (2021) Vol. Volume 14, pp. 3673-3689
Open Access | Times Cited: 15
PECAM-1 drives β-catenin-mediated EndMT via internalization in colon cancer with diabetes mellitus
Qing Wu, Xingxing Du, Jianing Cheng, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 6
Dual epigenetic changes in diabetes mellitus‐associated pancreatic ductal adenocarcinoma correlate with downregulation of E‐cadherin and worsened prognosis
Yutaro Hara, Hiroki Mizukami, Keisuke Yamazaki, et al.
The Journal of Pathology Clinical Research (2023) Vol. 9, Iss. 5, pp. 354-366
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top